Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism.
Vano-Galvan
Sergio
S
Department of Dermatology, Ramon y Cajal Universitary Hospital, Carretera de Colmenar km 9100, 28034, Madrid, Spain. sergiovano@yahoo.es
Fernandez-Guarino
Monserrat
M
Henriquez-Santana
Aythamy
A
De Las Heras
Elena
E
Calbacho
Maria
M
Jaen
Pedro
P
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D003873:Dermatitis, Exfoliative / Q000139:chemically induced* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D012867:Skin / Q000473:pathology
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate